Loading…
OGN
Organon & Co.
NYSE· Healthcare· Drug Manufacturers - General· CUSIP 68622V106
$13.750.00%Price as of Oct 23, 00:47 UTC · updated once a day, after the close
At a glance
Organon & Co. (OGN) is listed on NYSE and classified in Drug Manufacturers - General, part of the Healthcare sector. It is headquartered in Jersey City, United States and has 10,000 employees. The company is worth $3.61B and trades at 17.6x its earnings of the last twelve months; the median for its sector is 24.3x. Revenue was $6.22B in fiscal 2025, down 2.9% from the year before. Net income was $187M. The share price is within 3% of its 52-week high. It pays a dividend yielding 0.58%. 4 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Israel Englander (Millennium Management), at $46.61M. In that quarter, 4 of them reduced the position. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Key metrics
- Market cap
- $3.61B
- P/E
- 17.6x
- Forward P/E
- 3.8x
- P/B
- 3.6x
- Dividend yield
- 0.58%
- Payout
- 10.26%
- EPS
- $0.78
- ROE
- 24.04%
- Profit margin
- 3.41%
- Revenue growth
- -2.30%
- Beta
- 1.54
- 52-week high
- $13.83
- 52-week low
- $5.69
History
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -52.9% over 5Y.
today you would have $456.31▼ -54.4%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 5 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Year-end price | $7.17 | $14.92 | $14.42 | $27.93 | $30.45 | |
| P/E | 5.7x | 10.0x | 4.5x | 3.6x | 7.8x | 5.7x |
| P/S | 0.6x | 0.3x | 0.6x | 0.6x | 1.2x | 1.2x |
| P/B | — | 2.5x | 8.2x | — | — | — |
| EPS |
Fair price, seven ways
Seven formulas applied to the reported numbers, each with its assumption next to the result. None of them predicts a price.
Earnings
$8.20
Square root of 22.5 × earnings × book value. Blind to intangibles, so it undervalues software and brands.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Earnings
$18.94
Median P/E of 24.3 among peers in the sector.
Earnings
$4.47
Median P/E of 5.7 across this company’s own years on record.
Cash flow
$2.88
Cash flow growing 5.0% a year for 10 years, discounted at 10%, then 2.5% forever.
Operating
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Dividends
—
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| TLXTelix Pharmaceuticals Ltd | $10.69 | 106.9x | 7.4x | 0.00% | 7.37% | $3.63B |
| AMLXAmylyx Pharmaceuticals, Inc. | $28.57 | — | 13.3x | 0.00% | -74.73% | $3.59B |
| CDNACareDx, Inc. | $69.16 | 33.3x | 8.4x | 0.00% | 29.49% | $3.58B |
| LQDALiquidia Corp | $39.69 |
About the company
- 10,000
- Jersey City, United States